Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer

Background: Lapatinib (GW572016) is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/ErbB2), which are reported as overexpressed in 15%–45% of gastric cancers, making them potential targets. Patients and methods: The prima...

Descripción completa

Detalles Bibliográficos
Autores principales: Iqbal, S., Goldman, B., Fenoglio-Preiser, C. M., Lenz, H. J., Zhang, W., Danenberg, K. D., Shibata, S. I., Blanke, C. D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2011
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3221514/
https://www.ncbi.nlm.nih.gov/pubmed/21415234
http://dx.doi.org/10.1093/annonc/mdr021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3221514/
https://www.ncbi.nlm.nih.gov/pubmed/21415234
http://dx.doi.org/10.1093/annonc/mdr021

Ejemplares similares